Urinary Incontinence Pipeline Review H2 2017 report provides comprehensive information on the therapeutics for drugs under development for Urinary Incontinence, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. Urinary Incontinence Pipeline report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Urinary Incontinence and features dormant and discontinued projects. Urinary Incontinence Pipeline Review H2 2017 features investigational drugs therapeutics from across globe. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Get Discount On This Report at http://www.reportsnreports.com/contacts/discount.aspx?name=911471 .
Key companies analyzed In report are Astellas Pharma Inc, Celogos SA, Cook MyoSite Inc, FemmePharma Global Healthcare Inc, GTx Inc, Innovacell Biotechnologie AG, Ipsen SA, Outpost Medicine Ltd, Pfizer Inc, Taiho Pharmaceutical Co Ltd, Takeda Pharmaceutical Company Ltd.
Description of Report:
Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.The report provides a snapshot of the global therapeutic landscape of Urinary Incontinence. The report reviews pipeline therapeutics for Urinary Incontinence by companies and universities/research institutes based on information derived from company and industry-specific sources. The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.The report reviews key player’s involved Urinary Incontinence therapeutics and enlists all their major and minor projects. The report assesses Urinary Incontinence therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects. The report reviews latest news related to pipeline therapeutics for Urinary Incontinence
Purchase this Report at http://www.reportsnreports.com/purchase.aspx?name=911471 .
Drug Profiles analysed in report are (mirabegron + solifenacin succinate), abobotulinumtoxina, Cell Therapy for Ischemic Heart Failure, Gastrointestinal Disorders and Urological Diseases, Cell Therapy for Urinary Incontinence, enobosarm, Gtx-027, ICES-13, OP-233, oxybutynin chloride, Prof-003, RCD-1, Small Molecule to Agonize 5-HT2C for Urinary Incontinence, Small Molecule to Inhibit NET for Stress Urinary Incontinence, TAS-303.
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies. Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. Identify and understand important and diverse types of therapeutics under development for Urinary Incontinence. Identify potential new clients or partners in the target demographic. Develop strategic initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics. Devise corrective measures for pipeline projects by understanding Urinary Incontinence pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Major Table OF Content
- Number of Products under Development for Urinary Incontinence, H2 2017 14
- Number of Products under Development for Urinary Incontinence – Comparative Analysis, H2 2017 15
- Number of Products under Development by Companies, H2 2017 16
- Number of Products under Development by Companies, H2 2017 (Contd…1) 17
- Number of Products under Development by Companies, H2 2017 (Contd…2) 18
- Number of Products under Investigation by Universities/Institutes, H2 2017 19
- Comparative Analysis by Late Stage Development, H2 2017 20
- Comparative Analysis by Clinical Stage Development, H2 2017 21
- Comparative Analysis by Early Stage Development, H2 2017 22
- Products under Development by Companies, H2 2017 23
- Products under Development by Companies, H2 2017 (Contd…1) 24
- Products under Development by Companies, H2 2017 (Contd…2) 25
- Products under Investigation by Universities/Institutes, H2 2017 26
Reportsnreports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
2nd Floor, Metropole,
Bund Garden Road,
Pune – 411001,
Tel: + 1 888 391 5441